Gilead's Emvistegrast Meets Primary Endpoint in Phase 2 Ulcerative Colitis Trial

(AWP Alliance News) - Gilead Sciences announced that its experimental once-daily oral drug emvistegrast met the primary endpoint in the Phase 2 SWIFT trial in adults with moderately to severely active ulcerative colitis. The treatment improved clinical response and remission compared with placebo, with a generally well-tolerated safety profile.

Results from the 12-week induction phase were presented at United European Gastroenterology Week 2026 in Barcelona. Gilead plans to begin a Phase 3 monotherapy trial in 2027, with emvistegrast also under consideration as a backbone for future combination treatments.

The SWIFT trial remains ongoing, with maintenance-phase data and additional analyses planned.

https://www.publicnow.com/view/3A75E7AA2515802E68F650FA41B754FB4CF289F5…

Disclaimer: This news brief was created using generative artificial intelligence. Gilead Sciences Inc. published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.